Effects of Propofol vs. Sevoflurane Anesthesia on Ovarian Cancer Outcomes
Official title: Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Surgery for Primary Ovarian Cancer
Run by Kaohsiung Medical University Chung-Ho Memorial Hospital · NCT05606692 · Data updated 2026-11-12
This study tests whether using Propofol or Sevoflurane anesthesia during surgery for ovarian cancer affects recovery and survival for patients.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 20 Years to 80 Years |
| Sex | Women only |
| Enrollment | 416 (estimated) |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Kaohsiung City) |
| Status | Recruiting |
| Started | November 23, 2022 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2027 |
| Registry record updated | May 30, 2023 |
| Trial ID | NCT05606692 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 20 to 80 years with ASA class I-III undergoing elective surgery for primary ovarian tumors.
✕Probably not a fit
Patients with severe mental disorders, poor liver function, or those undergoing non-primary ovarian cancer surgeries may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of two different anesthetic agents, Propofol and Sevoflurane, on patients undergoing surgery for primary ovarian cancer. Participants are randomly assigned to receive either Propofol or Sevoflurane during their elective craniotomy, with careful monitoring of various clinical parameters such as vital signs, postoperative complications, and overall survival rates. The study aims to assess how the choice of anesthesia influences patient outcomes, including recovery and survival over a three-year period.
Why it matters
Potential benefit: If successful, this study could provide insights into optimizing anesthesia for improved survival and recovery in ovarian cancer patients.
How similar studies have gone: Other studies have shown varying results regarding the impact of anesthetic choice on cancer outcomes, making this investigation both relevant and necessary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Twenty to eighty-year-old. 2. ASA class I-III. 3. Patients undergoing elective craniotomy for primary ovarian tumors under general anesthesia. Exclusion Criteria: 1. Severe mental disorder 2. Poor liver function 3. Pregnant or lactating women 4. Morbid obesity 5. Have a history of allergy to any drug used in this study 6. Non-primary ovarian cancer surgery 7. Undergoing ovarian cancer pathological section surgery 8. Patients with incomplete medical records 9. Combined with other surgeries, emergency surgeries 10. Concomitant patients with other non-ovarian cancer therapy 11. Patients receiving palliative treatment after ovarian cancer surgery 12. During the maintenance period of anesthesia, propofol or sevoflurane should not be used as anesthetic drugs 13. Intraoperative combined use of multiple anesthetics (such as ketamine, dexmedetomidine, other inhalation anesthetics) 14. Those diagnosed with benign tumors before and after surgery 15. Patients with metastases to the ovary
Where it's running
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan Recruiting
Study contacts
- Principal investigator: Zhi-Fu Wu — Kaohsiung Medical University
- Study coordinator: Zhi-Fu Wu, MD
- Email: aneswu@gmail.com
- Phone: 07-3121101
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.